Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

January 24, 2017
Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic heading into Phase III with Swiss partner Helsinn. Phase II data presented at the American Society of Hematology meeting in December 2016 suggested a complete response rate of 42% and median survival of 19.1 months for the drug in combination with Celgene's Vidaza (azacitadine) in older, treatment-naive AML patients, which compares well to historical controls. Gold discussed his company's plans for a large Phase III study with Helsinn and implications for interest in subtypes of the disease during an interview at Biotech Showcase.
Previous Video
Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity
Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T...

Next Video
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 20...